Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 260-375-3 | CAS number: 56773-42-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: short-term oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: well documented and scientifically acceptable
Data source
Reference
- Reference Type:
- publication
- Title:
- Gestational and lactational exposure to potassium perfluorooctanesulfonate (K+PFOS) in rats: Developmental neurotoxicity
- Author:
- Butenhoff JL, Ehresman DJ, Chang SC, Parker GA, Stump DG
- Year:
- 2 009
- Bibliographic source:
- Reprod Toxicol 27, 319-330
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 426 (Developmental Neurotoxicity Study)
- Principles of method if other than guideline:
- examination of developmental neurotoxicity
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Potassium heptadecafluorooctane-1-sulphonate
- EC Number:
- 220-527-1
- EC Name:
- Potassium heptadecafluorooctane-1-sulphonate
- Cas Number:
- 2795-39-3
- IUPAC Name:
- potassium 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate
- Details on test material:
- K+PFOS (lot no. 217. 86 9% purity) was provided by 3M Company (Sr Paul. MN).
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl: CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 05% Tween® 20
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Doses were given once daily from GD 0 to PND 20 for the main study phase rats and from GD 0 to GD 19 for the satellite phase rats
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 0.1, 03, and 10 mg/kg-d
Basis:
nominal conc.
- No. of animals per sex per dose:
- 4 groups of 2 dose-groups in the main study
An additional 10 mated females were assigned as satellite phase rats to each of the 4 groups - Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 0.3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Remarks on result:
- other: Generation: maternal (migrated information)
- Dose descriptor:
- NOAEL
- Effect level:
- 0.3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Remarks on result:
- other: Generation: offspring (migrated information)
Any other information on results incl. tables
No significant effect was noted on maternal health or reproductive outcomes from dosing of maternal rats with K+PFOS throughout gestation. Maternal body weights were statistically significantly lower in the 1.0 mg/kg-d dosage group from PND 4 through the end oflactation. Offspring fram K+PFOS-treated maternal graups did not differ significantly from controls with respect to birth weight. growth, age and weight at attainment of sexual maturation, learning and memory, acoustic startle, various behavioral endpoints, and brain weight. Male offspring from the 1.0 mg/kg-d maternal treatment group displayed increased motor activity and reduced habituation on PND 17 but not on PND 13, 21, and 61. The maternal no-observed-adverse-effect-level (NOAEL) was 0.3 mg/kg-d based on decreased body weights observed in lactation. The maternal dose associated with the NOAEL for male offspring was 0.3 mg/kg-d based on increased motor activity and reduced habituation in the 1.0 mg/kg-d maternal dose-group male offspring on PND 17. The maternal dose associated with the NOAEL for female offspring was > 1.0 mg/kg-d.
Applicant's summary and conclusion
- Executive summary:
The objective of this study was to evaluate the functional and morphological changes to the nervous system in rats having gestational and lactational exposures to PFOS per current test guidelines (EPA OPPTS 870.6300 and OECD 426). Female SD rats (25/dosage group) were given daily oral doses of either 0.0, 01, 0.3, or 1.0 mg/kg-d potassium PFOS (K+PFOS) from gestation
day (GD) 0 through postnatal day (PND) 20. Offspring were observed through PND 72 for growth, maturation, motor activity, learning and memory, acoustic startle reflex, various behavioral manifestations, and brain weight. Specimens were taken from dams, fetuses, and pups for serum and tissue PFOS concentration, thyroid status end points, and liver mRNA transcript analysis. No significant effect was noted on maternal health or reproductive outcomes from dosing of maternal rats with K+PFOS throughout gestation. Maternal body weights were statistically significantly lower in the 1.0 mg/kg-d dosage group from PND 4 through the end of lactation. Offspring from K+PFOS-treated maternal graups did not differ significantly from contrals with respect to birth weight.
growth, age and weight at attainment of sexual maturation,learning and memory, acoustic startle, various behavioral endpoints, and brain weight. Male offspring from the 1.0 mg/kg-d maternal treatment group displayed increased motor activity and reduced habituation on PND 17 but not on PND 13, 21, and 61. The maternal no-observed-adverse-effect-Ievel (NOAEL) was 0.3 mg/kg-d based on decreased body weights observed in lactation. The maternal dose associated with the NOAEL for male offspring was 0.3 mg/kg-d based on increased motor activity and reduced habituation in the 1.0 mg/kg-d maternal dose-group male offspring on PND 17. The maternal dose associated with the NOAEL for female offspring was> 1.0 mg/kg-d. Mean serum concentrations of PFOS are several hundred times higher than those reported for females in the Uni ted States general population.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
